Zimmer has reported net sales of $1.06bn for the second quarter 2010, an increase of 3.7%, compared to the second quarter of 2009. The company also posted $0.82 diluted earnings per share and $1.09 adjusted for the second quarter, an increase of 9% compared to the second quarter of 2009.
Zimmer has posted net earnings of $165.5m for the second quarter on a reported basis and $221.2m on an adjusted basis, an increase of 2.6% adjusted, compared to the prior year period.
For the six months ended 2010, the company posted net earnings of $370.9m on a reported basis and $428.6m on an adjusted basis, an increase of 0.7% adjusted over the prior year period.
Zimmer recorded an additional $75m provision for known and anticipated worldwide claims related to the previously announced voluntary suspension of marketing and distribution of the Durom Acetabular Component in the US.
David Dvorak, president and CEO of Zimmer, said: “Our second quarter performance was characterized by year-over-year constant currency sales growth in all geographic segments, strong earnings and cash flow, and the continued introduction of important new products and instruments.
“We anticipate accelerated growth through 2010 as these new offerings augment our portfolio of clinically-proven solutions.”